BIS-TRIMETHYLBENZOYL PHENYLPHOSPHINE OXIDE
連携データベース 14 · 대한화장품협회 성분사전, 미국 CIR 안전성 평가, 미국 EPA 화학물질 DB, 미국 EPA CompTox +10
定義
미국 FDA 물질 등록 · UNII JOV61FMS35 · 등록명 BIS-TRIMETHYLBENZOYL PHENYLPHOSPHINE OXIDE · 단일 화학물질
Bis-Trimethylbenzoyl Phenylphosphine Oxide is the organic compound.
이 원료는 다음의 구조를 갖는 유기화합물이다.
출처: 식약처 화장품 원료성분
公式表示名・定義
JCIA 표시명 ビストリメチルベンゾイルフェニルホスフィンオキシド: 本品は、次の化学式で表される有機化合物である。
출처: 일본 화장품공업연합회 표시명
別名・識別情報
- CAS No.化学物質登録番号
- 162881-26-7
- DTXSID米国EPA化学物質番号
- DTXSID8044597
- DTXCID米国EPA化合物番号
- DTXCID6024597
- IUPAC
- Phenylbis(2,4,6-trimethylbenzoyl)-lambda~5~-phosphanone
- 분자식
- C26H27O3P
- 분자량
- 418.473 g/mol
化粧品での役割
この成分を含む製品
확인된 7개 중 7개 · 무작위 순서
安全性・規制情報
국내 유독물 GHS 분류 없음 · 기존화학물질
CIR reviewed this ingredient and flagged its status as: Insufficient Data Announcement: Safety Assessment of Bis Trimethylbenzoyl PhenylphosphineOxide, Ethyl Trimethylbenzoyl Phenylphosphinate, andTrimethylbenzoyl Diphenylphosphine Oxide (insufficient data or use not supported — CIR's own classification, not a full safety-as-used conclusion).
출처: 미국 CIR 안전성 평가
製品が実際に使っている用途
미국 EPA에 이 성분을 신고한 제품 13건의 용도입니다. 화장품 밖의 제품도 포함되어 있어, 위쪽 몇 줄이 이 성분의 주된 쓰임으로 읽힌다는 뜻입니다.
- 광증감제6
- 공정 보조3
- 감광제2
- 촉매1
- 안정화제1
출처: 미국 EPA CompTox
刺激・感作試験の記録
피부 시험 15건 · 눈 시험 5건이 기록되어 있습니다.
시험 결론이 대체로 일치합니다(100%). 원료 자체를 시험한 기록이고, 완제품에 든 농도에서의 자극성과는 다릅니다.
시험 20건 전부 보기
- Skin Sens. 1
Skin Sensitization · Authoritative - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC (maximisation), B.6 - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC (maximisation) - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) (92/69/EEC) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: 92/69/EEC, B.4 according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: 92/69/EEC according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) (Directive 92/69/EEC) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to EU Method B.6 (Skin Sensitisation) - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC (Maximisation) - Ambiguous
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to OECD Guideline 406 (Skin Sensitisation) (1992) - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to EU Method B.6 (Skin Sensitisation) (Directive 92/69/EEC) - Ambiguous
skin sensitisation · Screening · according to other guideline: 92/69/EEC (Maximisation)
